TIL

Instil Bio, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website instilbio.com
Employees(FY) 192
ISIN US45783C2008

Performance

-3.83%

-21.34%

-64.92%

+109.03%

+170.47%

YTD

+196.55%

Profile

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Advanced Technical Analysis

Technical Analysis of TIL 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, a neutral Oscillators Score of 50 suggesting indecision, and a Technical Score of 30 reinforcing the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to be nega...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TIL

Stock Rank

Recent News & Updates

2024-11-12 18:00
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-10-22 13:01
Analysis of Curative Ventures V LLC's Strategic Reduction in Instil Bio Inc(Yahoo Finance)
2024-09-27 09:43
BOXER CAPITAL, LLC Acquires New Stake in Instil Bio Inc(Yahoo Finance)
2024-09-27 07:03
Perceptive Advisors LLC Acquires New Stake in Instil Bio Inc(Yahoo Finance)
2024-09-24 16:56
2 Stocks Up Over 700% in 2024 That Could Soar Even Further(Yahoo Finance)
2024-09-16 16:24
Here's Why Everyone's Talking About Summit Therapeutics(Yahoo Finance)
2024-09-16 06:00
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer(GlobeNewswire)
2024-09-15 18:00
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer(Globenewswire)
2024-09-14 04:56
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?(Motley Fool)
2024-09-10 13:08
Private equity firms are Instil Bio, Inc.'s (NASDAQ:TIL) biggest owners and were rewarded after market cap rose by US$52m last week(Simply Wall St.)
2024-08-13 17:00
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update(GlobeNewswire)
2024-08-13 10:53
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024(Investorplace)
2024-08-13 05:00
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-08-01 06:00
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody(GlobeNewswire)
2024-07-31 18:00
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody(Globenewswire)
2024-07-12 07:37
Top Premarket Gainers(MT Newswires)
2024-07-11 19:41
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday(Investorplace)
2024-07-11 17:51
Instil Bio Signs Lease With AstraZeneca Pharmaceuticals at California Facility; Shares Rise After Hours(MT Newswires)
2024-05-10 01:54
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024(Investorplace)
2024-05-09 19:00
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-03-27 00:00
What Makes Instil Bio (TIL) a New Buy Stock(Zacks)
2024-03-21 10:52
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023(Investorplace)
2024-03-21 05:00
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update(Globenewswire)
2024-01-17 23:28
Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why(Yahoo Finance)
2024-01-15 19:00
Instil Bio Announces Strategic Update(Globenewswire)
2023-12-12 21:52
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023(Investorplace)
2023-12-12 21:51
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023(Investorplace)
2023-12-05 04:00
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split(Globenewswire)
2023-11-13 04:00
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update(Globenewswire)
2023-11-05 18:00
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.